Find information on thousands of medical conditions and prescription drugs.

Cefixime

Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. Cefixime is still available in Canada. It is used to treat gonorrhea.

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Comparative evaluation of the efficacy, safety and tolerability of Extended-Release cefuroxime axetil tablets 500 mg and cefixime tablets 200 mg in
From CHEST, 10/1/05 by Anish A. Desai

PURPOSE: A new Extended -Release(ER) formulation of Cefuroxime axetil 500 mg tablets has been recently developed. This pilot study was undertaken to compare the efficacy, safety and tolerability of this new formulation and Cefixime tablets in patients with acute tonsillopharyngitis.

METHODS: Adult patients (n = 100) with a clinical diagnosis of acute pharyngotonsillitis, fulfilling the selection criteria were enrolled in this prospective, multicentric, randomized, assessor-blind, comparative pilot study after obtaining their informed consent. Patients were randomized to receive either 500 mg ER- Cefuroxime axetil tablets once-daily or cefixime 200 mg tablets twice daily for 10 days. Efficacy outcomes included monitoring of clinical and bacteriological response at end of therapy. Safety and tolerability were assessed by monitoring adverse events and laboratory parameters.

RESULTS: A total of 96 patients completed the study with 4 drop-outs (2 from each group) being lost to follow-up. There was a significant decline in mean scores of sore throat, dysphagia, tonsillar erythema, pharyngeal or tonsillar exudate and tender anterior cervical nodes from baseline at end of treatment in both groups. However, difference between groups was not statistically significant. Cure was observed in 91.7% patients in ER-Cefuroxime axetil group and 93.7% patients in cefixime group at end of study (p>0.05). Bacteriological response was observed in similar number of patients in both groups(ER-Cefuroxime axetil (95.8%); Cefixime (97.9%)) at end of therapy. Similar incidences of mild to moderate adverse events mostly gastrointestinal in nature were reported in both groups (ER-Cefuroxime axetil 6% & cefixime--8%). No abnormalities were detected in the laboratory parameters.

CONCLUSION: ER-Cefuroxime axetil tablets once daily were comparable in efficacy, safety and tolerability to Cefixime tablets twice daily in patients with acute tonsillopharyngitis.

CLINICAL IMPLICATIONS: Once-daily ER-Cefuroxime axetil is a better therapeutic option than twice daily cefixime tablets in patients with acute tonsillopharyngitis on account of its dosage convenience.

DISCLOSURE: Anish Desai, None.

Anish A. Desai MD * U Venkatesan MD G S. Kadam MD Ashish S. Gawde MD Vidyagauri P. Baliga PhD Glenmark Pharmaceuticals Ltd, Mumbai, India

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Cefixime
Home Contact Resources Exchange Links ebay